Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Eur Radiol

Retrieve available abstracts of 20 articles:
HTML format
Text format



Single Articles


    June 2017
  1. BATES A, Miles K
    Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer.
    Eur Radiol. 2017 Jun 12. doi: 10.1007/s00330-017-4877.
    PubMed     Text format     Abstract available


    May 2017
  2. GIGANTI F, Moore CM, Robertson NL, McCartan N, et al
    MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial.
    Eur Radiol. 2017 May 18. doi: 10.1007/s00330-017-4858.
    PubMed     Text format     Abstract available


  3. DE VISSCHERE PJ, Vral A, Perletti G, Pattyn E, et al
    Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate.
    Eur Radiol. 2017;27:2095-2109.
    PubMed     Text format     Abstract available


  4. ROUVIERE O, Melodelima C, Hoang Dinh A, Bratan F, et al
    Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study.
    Eur Radiol. 2017;27:1858-1866.
    PubMed     Text format     Abstract available


    April 2017
  5. OVERDUIN CG, Jenniskens SF, Sedelaar JP, Bomers JG, et al
    Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes.
    Eur Radiol. 2017 Apr 13. doi: 10.1007/s00330-017-4833.
    PubMed     Text format     Abstract available


  6. WANG J, Wu CJ, Bao ML, Zhang J, et al
    Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer.
    Eur Radiol. 2017 Apr 3. doi: 10.1007/s00330-017-4800.
    PubMed     Text format     Abstract available


  7. BOMERS JG, Bosboom DG, Tigelaar GH, Sabisch J, et al
    Feasibility of a 2nd generation MR-compatible manipulator for transrectal prostate biopsy guidance.
    Eur Radiol. 2017;27:1776-1782.
    PubMed     Text format     Abstract available


    December 2016
  8. WILDEBOER RR, Postema AW, Demi L, Kuenen MP, et al
    Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer.
    Eur Radiol. 2016 Dec 21. doi: 10.1007/s00330-016-4693.
    PubMed     Text format     Abstract available


  9. NKETIAH G, Elschot M, Kim E, Teruel JR, et al
    T2-weighted MRI-derived textural features reflect prostate cancer aggressiveness: preliminary results.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  10. SCHIMMOLLER L, Quentin M, Blondin D, Dietzel F, et al
    Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?
    Eur Radiol. 2016;26:3858-3864.
    PubMed     Text format     Abstract available


    September 2016
  11. SIDHU HS, Benigno S, Ganeshan B, Dikaios N, et al
    "Textural analysis of multiparametric MRI detects transition zone prostate cancer".
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  12. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.
    Eur Radiol. 2016;26:2502-9.
    PubMed     Text format     Abstract available


    July 2016
  13. ROSSET R, Bratan F, Crouzet S, Tonoli-Catez H, et al
    Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer?
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


  14. VAN DEN BOS W, de Bruin DM, van Randen A, Engelbrecht MR, et al
    MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    Eur Radiol. 2016;26:2252-60.
    PubMed     Text format     Abstract available


    June 2016
  15. BARBIERI S, Bronnimann M, Boxler S, Vermathen P, et al
    Differentiation of prostate cancer lesions with high and with low Gleason score by diffusion-weighted MRI.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


  16. MARTIN J, Arm J, Smart J, Palazzi K, et al
    Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  17. KIM CK, Park JJ, Park BK
    Prostate diffusion-weighted imaging at 3T: effect of intravenous gadobutrol administration.
    Eur Radiol. 2016;26:1450-6.
    PubMed     Text format     Abstract available


    April 2016
  18. DE VISSCHERE PJ, Naesens L, Libbrecht L, Van Praet C, et al
    What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?
    Eur Radiol. 2016;26:1098-107.
    PubMed     Text format     Abstract available


    March 2016
  19. DERLIN T, Weiberg D, von Klot C, Wester HJ, et al
    Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  20. WOO S, Kim SY, Lee J, Kim SH, et al
    PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: